C Partners Holding’s Jazz Pharmaceuticals JAZZ Stock Holding History

C Partners Holding’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-675	Closed	-$113K	–	126
2018 Q3	$113K	Sell	675 -760	-53%	-$131K	0.04%	198
2018 Q2	$247K	Sell	1,435 -94	-6%	-$15.4K	0.09%	52
2018 Q1	$231K	Sell	1,529 -325	-18%	-$47.7K	0.1%	57
2017 Q4	$250K	Buy	+1,854	New	+$257K	0.1%	226

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

C Partners Holding's JAZZ Position: Q4 2018 in Review

C Partners Holding sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 675 shares — an estimated $113K sold.

C Partners Holding first reported a position in JAZZ in Q4 2017 and held it in 4 quarters. The position peaked at $250K in Q4 2017. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

C Partners Holding reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
C Partners Holding sold 675 Jazz Pharmaceuticals shares in Q4 2018, an estimated $113K.
C Partners Holding first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 4 quarters.
C Partners Holding's Jazz Pharmaceuticals position peaked at $250K in Q4 2017.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on C Partners Holding's 13F filing for Q4 2018, filed 7 Feb 2019.